New CLL data presented for Zydelig, venetoclax

Data expected to support regulatory submissions of Zydelig idelalisib from Gilead Sciences Inc. (NASDAQ:GILD) and venetoclax (ABT-199) from Roche (SIX:ROG; OTCQX:RHHBY) and AbbVie Inc. (NYSE:ABBV) to treat chronic lymphocytic leukemia were presented at the American Society of Hematology (ASH) meeting in Orlando.

In a Phase III trial, Zydelig plus Treanda bendamustine and Rituxan rituximab led to a 67% reduction in disease progression or death compared to patients receiving Treanda and Rituxan alone (HR=0.33; 95% CI: 0.24, 0.45; p<0.0001). The median PFS for patients receiving the Zydelig combination therapy was 23.1 months vs. 11.1 months for patients receiving placebo plus standard therapy. ...